Development of a Lateral Flow Assay for the Detection of the Hepatitis C Virus Core Antigen.

Erick Joan Vidal-Alcántara, Sonia Hernández Antón, Paloma Rueda, María Belén Yélamos, Julián Gómez, Salvador Resino, Alba Fresco-Taboada, Isidoro Martínez
Author Information
  1. Erick Joan Vidal-Alcántara: Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain.
  2. Sonia Hernández Antón: Gold Standard Diagnostics Madrid S.A (GSD Madrid), Calle de los Hermanos García Noblejas, 39, 28037 Madrid, Spain.
  3. Paloma Rueda: Gold Standard Diagnostics Madrid S.A (GSD Madrid), Calle de los Hermanos García Noblejas, 39, 28037 Madrid, Spain. ORCID
  4. María Belén Yélamos: Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas, Universidad Complutense, 28040 Madrid, Spain. ORCID
  5. Julián Gómez: Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Químicas, Universidad Complutense, 28040 Madrid, Spain. ORCID
  6. Salvador Resino: Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain. ORCID
  7. Alba Fresco-Taboada: Gold Standard Diagnostics Madrid S.A (GSD Madrid), Calle de los Hermanos García Noblejas, 39, 28037 Madrid, Spain. ORCID
  8. Isidoro Martínez: Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, 28220 Madrid, Spain. ORCID

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection remains a global health challenge, with millions of people affected annually. Current diagnostic methods, reliant on antibody screening and viral RNA detection, are complex, costly, and often inaccessible, particularly in resource-limited settings.
AIM: Development of a lateral flow immunochromatography-based assay for detecting the highly conserved hepatitis C core antigen (HCVcAg).
METHODS: The assay relies on the interaction of four highly specific and cross-reactive monoclonal antibodies with recombinant HCVcAg from five different genotypes in a double antibody sandwich format. Latex and colloidal gold were evaluated as detector nanoparticles.
RESULTS: Extensive evaluation of 32 antibody combinations led to identifying the most sensitive antibody pairs. The chosen assay, named LN17, demonstrated a target sensitivity of 10 ng/strip, with potential clinical implications for detecting HCV. Furthermore, the study examined matrix effects in serum samples, providing valuable insights for future clinical application.
CONCLUSIONS: The developed assay holds promise as a rapid, cost-effective, and user-friendly tool to enhance accessibility to hepatitis C screening, especially in high-risk populations and resource-limited environments.

Keywords

References

  1. Enferm Infecc Microbiol Clin (Engl Ed). 2020 Jan;38 Suppl 1:12-18 [PMID: 32111360]
  2. Front Bioeng Biotechnol. 2022 Jun 14;10:922772 [PMID: 35774059]
  3. Front Mol Biosci. 2023 Jul 13;10:1225553 [PMID: 37520323]
  4. Arch Virol. 2020 Mar;165(3):627-641 [PMID: 31965313]
  5. Essays Biochem. 2016 Jun 30;60(1):111-20 [PMID: 27365041]
  6. Curr Top Microbiol Immunol. 2013;369:113-42 [PMID: 23463199]
  7. Clin Chem Lab Med. 2018 May 24;56(6):880-888 [PMID: 29702484]
  8. Lancet Microbe. 2023 Aug;4(8):e622-e631 [PMID: 37336226]
  9. Hepatology. 2002 Jul;36(1):211-8 [PMID: 12085367]
  10. Nucleosides Nucleotides Nucleic Acids. 2013;32(2):59-68 [PMID: 23448141]
  11. World J Gastroenterol. 2015 Oct 14;21(38):10811-23 [PMID: 26478672]
  12. World J Hepatol. 2017 Mar 8;9(7):352-367 [PMID: 28321272]
  13. Hepatology. 1996 Nov;24(5):1003-9 [PMID: 8903367]
  14. Pathogens. 2023 Jun 07;12(6): [PMID: 37375501]
  15. Lancet. 2019 Oct 19;394(10207):1451-1466 [PMID: 31631857]
  16. Clin Microbiol Infect. 2010 Aug;16(8):1054-61 [PMID: 20670287]
  17. J Viral Hepat. 1995;2(5):235-41 [PMID: 8745315]
  18. Transfusion. 2015 Oct;55(10):2489-98 [PMID: 26013970]
  19. Lancet Glob Health. 2021 Apr;9(4):e431-e445 [PMID: 33639097]
  20. Transfusion. 2000 Oct;40(10):1198-202 [PMID: 11061855]
  21. J Clin Virol. 2021 Jul;140:104846 [PMID: 33971580]
  22. J Clin Microbiol. 2017 Aug;55(8):2313-2320 [PMID: 28539345]
  23. J Virol Methods. 2009 Jun;158(1-2):160-4 [PMID: 19428585]
  24. Biosensors (Basel). 2023 Aug 23;13(9): [PMID: 37754072]
  25. J Clin Microbiol. 2001 Sep;39(9):3110-4 [PMID: 11526137]
  26. Vox Sang. 2000;78(2):80-5 [PMID: 10765142]
  27. Biosens Bioelectron. 2023 Feb 15;222:115006 [PMID: 36538869]
  28. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8239-43 [PMID: 8058787]

Grants

  1. PI19CIII/00009/Instituto de Salud Carlos III
  2. CB21/13/00044/Centro de Investigación Biomédica en Red de Enfermedades infecciosas (CIBERINFEC)

Word Cloud

Created with Highcharts 10.0.0CantibodyassayhepatitisHepatitisHCVdiagnosticscreeningresource-limitedDevelopmentdetectinghighlycoreantigenHCVcAgmonoclonalclinicalrapidBACKGROUND:virusinfectionremainsglobalhealthchallengemillionspeopleaffectedannuallyCurrentmethodsreliantviralRNAdetectioncomplexcostlyofteninaccessibleparticularlysettingsAIM:lateralflowimmunochromatography-basedconservedMETHODS:reliesinteractionfourspecificcross-reactiveantibodiesrecombinantfivedifferentgenotypesdoublesandwichformatLatexcolloidalgoldevaluateddetectornanoparticlesRESULTS:Extensiveevaluation32combinationsledidentifyingsensitivepairschosennamedLN17demonstratedtargetsensitivity10ng/strippotentialimplicationsFurthermorestudyexaminedmatrixeffectsserumsamplesprovidingvaluableinsightsfutureapplicationCONCLUSIONS:developedholdspromisecost-effectiveuser-friendlytoolenhanceaccessibilityespeciallyhigh-riskpopulationsenvironmentsLateralFlowAssayDetectionVirusCoreAntigentest

Similar Articles

Cited By (1)